Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/08—Esters of oxyacids of phosphorus
  • C07F9/09—Esters of phosphoric acids
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B29/00—Monoazo dyes prepared by diazotising and coupling
  • C09B29/0025—Monoazo dyes prepared by diazotising and coupling from diazotized amino heterocyclic compounds
  • C09B29/0074—Monoazo dyes prepared by diazotising and coupling from diazotized amino heterocyclic compounds the heterocyclic ring containing nitrogen and sulfur as heteroatoms
  • C09B29/0077—Monoazo dyes prepared by diazotising and coupling from diazotized amino heterocyclic compounds the heterocyclic ring containing nitrogen and sulfur as heteroatoms containing a five-membered heterocyclic ring with one nitrogen and one sulfur as heteroatoms
  • C09B29/0085—Thiazoles or condensed thiazoles
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B57/00—Other synthetic dyes of known constitution
  • C09B57/02—Coumarine dyes
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/101—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an anthracene dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/101—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an anthracene dye
  • C09B69/102—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an anthracene dye containing a perylene dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/103—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing a diaryl- or triarylmethane dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/105—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing a methine or polymethine dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/109—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing other specific dyes
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
  • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
  • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N1/00—Sampling; Preparing specimens for investigation
  • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
  • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
  • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
  • G01N21/64—Fluorescence; Phosphorescence
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/483—Physical analysis of biological material
  • G01N33/487—Physical analysis of biological material of liquid biological material
  • G01N33/49—Blood
  • G01N33/4915—Blood using flow cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/531—Production of immunochemical test materials
  • G01N33/532—Production of labelled immunochemicals
  • G01N33/533—Production of labelled immunochemicals with fluorescent label

Definitions

• the present invention is generally directed to dimeric and polymeric fluorescent or colored dyes, and methods for their preparation and use in various analytical methods.
• Fluorescent and/or colored dyes are known to be particularly suitable for applications in which a highly sensitive detection reagent is desirable. Dyes that are able to preferentially label a specific ingredient or component in a sample enable the researcher to determine the presence, quantity and/or location of that specific ingredient or component. In addition, specific systems can be monitored with respect to their spatial and temporal distribution in diverse environments.
• Fluorescence and colorimetric methods are extremely widespread in chemistry and biology. These methods give useful information on the presence, structure, distance, orientation, complexation and/or location for biomolecules.
• time-resolved methods are increasingly used in measurements of dynamics and kinetics.
• many strategies for fluorescence or color labeling of biomolecules, such as nucleic acids and protein have been developed. Since analysis of biomolecules typically occurs in an aqueous environment, the focus has been on development and use of water soluble dyes.
• embodiments of the present invention are generally directed to compounds useful as water soluble, fluorescent and/or colored dyes and/or probes that enable visual detection of analyte molecules, such as biomolecules, as well as reagents for their preparation. Methods for visually detecting analyte molecules using the dyes are also described.
• the water soluble, fluorescent or colored dyes of embodiments of the invention are intensely colored and/or fluorescent and can be readily observed by visual inspection or other means. In some embodiments the compounds may be observed without prior illumination or chemical or enzymatic activation. By appropriate selection of the dye, as described herein, visually detectable analyte molecules of a variety of colors may be obtained.
• a method for staining a sample comprises adding to said sample a compound of structure (I) in an amount sufficient to produce an optical response when said sample is illuminated at an appropriate wavelength.
• the present disclosure provides a method for visually detecting an analyte molecule, comprising:
• Other disclosed methods include a method for visually detecting a biomolecule, the method comprising:
• R 2 or R 3 comprises a linker comprising a covalent bond to a targeting moiety having specificity for the analyte
• compositions comprising a compound of structure (I) and one or more analyte molecule, such as a biomolecule. Use of such compositions in analytical methods for detection of the one or more biomolecules is also provided.
• Some other embodiments include a composition comprising a compound of structure (I) and a cyclodextrin.
• a method for determining the presence of dead cells in a sample comprising contacting the sample with a compound of structure (I), thereby binding or associating the compound with the dead cells, and observing a fluorescent signal from the compound bound or associated with the dead cells.
• Amino refers to the -NH 2 group.
• Carboxy refers to the -C0 2 H group.
• Cyano refers to the -CN group.
• Alkyl refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms (Ci-Ci 2 alkyl), one to eight carbon atoms (Ci-C 8 alkyl) or one to six carbon atoms (Ci-C 6 alkyl), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, ⁇ -propyl, 1-methylethyl (z ' so-propyl), «-butyl, «-pentyl, 1, 1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, alkyl groups are optionally substituted.
• Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation, and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, «-butylene, ethenylene, propenylene, «-butenylene, propynylene, «-butynylene, and the like.
• the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
• the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkylene is optionally substituted.
• alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene, «-butenylene, and the like.
• the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
• the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkenylene is optionally substituted.
• Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene, «-butenylene, and the like.
• the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
• the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkynylene is optionally substituted.
• Alkylether refers to any alkyl group as defined above, wherein at least one carbon-carbon bond is replaced with a carbon-oxygen bond.
• the carbon-oxygen bond may be on the terminal end (as in an alkoxy group) or the carbon oxygen bond may be internal (i.e., C-O-C).
• Alkylethers include at least one carbon oxygen bond, but may include more than one.
• PEG polyethylene glycol
• an alkylether group is optionally substituted.
• Alkoxy refers to a group of the formula -OR a where R a is an alkyl group as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group is optionally substituted.
• Heteroalkyl refers to an alkyl group, as defined above, comprising at least one heteroatom (e.g., N, O, P or S) within the alkyl group or at a terminus of the alkyl group.
• the heteroatom is within the alkyl group (i.e., the heteroalkyl comprises at least one carbon-[heteroatom] x -carbon bond, where x is 1, 2 or 3).
• the heteroatom is at a terminus of the alkyl group and thus serves to join the alkyl group to the remainder of the molecule (e.g., Ml-H-A), where Ml is a portion of the molecule, H is a heteroatom and A is an alkyl group).
• a heteroalkyl group is optionally substituted.
• Exemplary heteroalkyl groups include ethylene oxide (e.g., polyethylene oxide), optionally including phosphorous-oxygen bonds, such as phosphodiester bonds.
• Heteroalkoxy refers to a group of the formula -OR a where R a is a heteroalkyl group as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a heteroalkoxy group is optionally substituted.
• Heteroalkylene refers to an alkylene group, as defined above, comprising at least one heteroatom (e.g., N, O, P or S) within the alkylene chain or at a terminus of the alkylene chain.
• the heteroatom is within the alkylene chain (i.e., the heteroalkylene comprises at least one carbon-[heteroatom] x - carbon bond, where x is 1, 2 or 3).
• the heteroatom is at a terminus of the alkylene and thus serves to join the alkylene to the remainder of the molecule (e.g., M1-H-A-M2, where Ml and M2 are portions of the molecule, H is a heteroatom and A is an alkylene).
• a heteroalkylene group is optionally substituted.
• heteroalkylene linking group include ethylene oxide (e.g., PEG) linkers and the linker illustrated below:
• Heteroalkenylene is a heteroalkylene, as defined above, comprising at least one carbon-carbon double bond. Unless stated otherwise specifically in the specification, a heteroalkenylene group is optionally substituted.
• Heteroalkynylene is a heteroalkylene comprising at least one carbon- carbon triple bond. Unless stated otherwise specifically in the specification, a heteroalkynylene group is optionally substituted.
• Heteroatomic in reference to a “heteroatomic linker” refers to a linker group consisting of one or more heteroatoms.
• R b is OH, O " , OR c , a thiophosphate group or a further phosphate group, wherein R c is a counter ion (e.g., Na+ and the like).
• R b is -Oalkyl, wherein R c is a counter ion (e.g., Na+ and the like).
• a phosphoalkyl group is optionally substituted.
• the -Oalkyl moiety in a phosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl,
• R a is O or S
• R b is OH, O " , S “ , OR d or SR d
• R c is OH, SH, O
• thiophosphoalkyl group is optionally substituted.
• R a is O or S
• R b is OH, O " , S " , OR d or SR3 ⁇ 4
• R c is -Oalkylether
• R d is a counter ion (e.g., Na+ and the like) and provided that: i) R a is S; ii) R b is S “ or SR d ; or iii)R a is S and R b is S " or SR d .
• a thiophosphoalkylether group is optionally substituted.
• the -Oalkylether moiety in a thiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether, thiophosphoalkylether or
• Carbocyclic refers to a stable 3- to 18-membered aromatic or non-aromatic ring comprising 3 to 18 carbon atoms. Unless stated otherwise specifically in the specification, a carbocyclic ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems, and may be partially or fully saturated. Non-aromatic carbocyclyl radicals include cycloalkyl, while aromatic carbocyclyl radicals include aryl. Unless stated otherwise specifically in the specification, a carbocyclic group is optionally substituted.
• Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
• Monocyclic cyclocalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptly, and cyclooctyl.
• Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo-[2.2.1]heptanyl, and the like. Unless stated otherwise specifically in the specification, a cycloalkyl group is optionally substituted.
• Aryl refers to a ring system comprising at least one carbocyclic aromatic ring.
• an aryl comprises from 6 to 18 carbon atoms.
• the aryl ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
• Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, an aryl group is optionally substituted.
• Heterocyclic refers to a stable 3- to 18-membered aromatic or non-aromatic ring comprising one to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
• the heterocyclic ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclic ring may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclic ring may be partially or fully saturated.
• heteroaryls examples include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, pyrazolopyrimidinyl, quinuclidinyl, thiazolid
• Heteroaryl refers to a 5- to 14-membered ring system comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
• the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
• Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[£][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl,
• Fused refers to a ring system comprising at least two rings, wherein the two rings share at least one common ring atom, for example two common ring atoms.
• the fused ring is a heterocyclyl ring or a heteroaryl ring
• the common ring atom(s) may be carbon or nitrogen.
• Fused rings include bicyclic, tricyclic, tertracyclic, and the like.
• substituted used herein means any of the above groups (e.g., alkyl, alkylene, alkenylene, alkynylene, heteroalkyl ene, heteroalkenylene,
• heteroalkynylene alkoxy, alkylether, alkoxyalkylether, heteroalkyl, heteroalkoxy, phosphoalkyl, phosphoalkylether, thiophosphoalkyl, thiophosphoalkylether, carbocyclic, cycloalkyl, aryl, heterocyclic and/or heteroaryl) wherein at least one hydrogen atom (e.g., 1, 2, 3 or all hydrogen atoms) is replaced by a bond to a non- hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines,
• “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
• R g and R h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
• Substituted further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
• each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
• Conjugation refers to the overlap of one p-orbital with another p- orbital across an intervening sigma bond. Conjugation may occur in cyclic or acyclic compounds.
• a “degree of conjugation” refers to the overlap of at least one p-orbital with another p-orbital across an intervening sigma bond. For example, 1, 3-butadine has one degree of conjugation, while benzene and other aromatic compounds typically have multiple degrees of conjugation. Fluorescent and colored compounds typically comprise at least one degree of conjugation.
• Fluorescent refers to a molecule which is capable of absorbing light of a particular frequency and emitting light of a different frequency. Fluorescence is well- known to those of ordinary skill in the art.
• Cold refers to a molecule which absorbs light within the colored spectrum (i.e., red, yellow, blue and the like).
• a “linker” refers to a contiguous chain of at least one atom, such as carbon, oxygen, nitrogen, sulfur, phosphorous and combinations thereof, which connects a portion of a molecule to another portion of the same molecule or to a different molecule, moiety or solid support (e.g., microparticle). Linkers may connect the molecule via a covalent bond or other means, such as ionic or hydrogen bond interactions.
• biomolecule refers to any of a variety of biological materials, including nucleic acids, carbohydrates, amino acids, polypeptides, glycoproteins, hormones, aptamers and mixtures thereof.
• the visually detectable biomolecules of the invention e.g., compounds of structure (I) having a biomolecule linked thereto
• a “reactive group” is a moiety capable of reacting with a second reactive groups (e.g., a “complementary reactive group”) to form one or more covalent bonds, for example by a displacement, oxidation, reduction, addition or cycloaddition reaction.
• Exemplary reactive groups are provided in Table 1, and include for example, nucleophiles, electrophiles, dienes, dienophiles, aldehyde, oxime, hydrazone, alkyne, amine, azide, acylazide, acylhalide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester, ketone, ⁇ , ⁇ -unsaturated carbonyl, alkene, maleimide, a-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin, thiirane and the like.
• visible and “visually detectable” are used herein to refer to substances that are observable by visual inspection, without prior illumination, or chemical or enzymatic activation. Such visually detectable substances absorb and emit light in a region of the spectrum ranging from about 300 to about 900 nm. Preferably, such substances are intensely colored, preferably having a molar extinction coefficient of at least about 40,000, more preferably at least about 50,000, still more preferably at least about 60,000, yet still more preferably at least about 70,000, and most preferably at least about 80,000 M ⁇ cm "1 .
• the compounds of the invention may be detected by observation with the naked eye, or with the aid of an optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners.
• Visually detectable substances are not limited to those which emit and/or absorb light in the visible spectrum. Substances which emit and/or absorb light in the ultraviolet (UV) region (about 10 nm to about 400 nm), infrared (IR) region (about 700 nm to about 1 mm), and substances emitting and/or absorbing in other regions of the electromagnetic spectrum are also included with the scope of "visually detectable" substances.
• UV ultraviolet
• IR infrared
• the term "photostable visible dye” refers to a chemical moiety that is visually detectable, as defined hereinabove, and is not significantly altered or decomposed upon exposure to light.
• the photostable visible dye does not exhibit significant bleaching or decomposition after being exposed to light for at least one hour. More preferably, the visible dye is stable after exposure to light for at least 12 hours, still more preferably at least 24 hours, still yet more preferably at least one week, and most preferably at least one month.
• Nonlimiting examples of photostable visible dyes suitable for use in the compounds and methods of the invention include azo dyes, thioindigo dyes,
• quinacridone pigments dioxazine, phthalocyanine, perinone, diketopyrrolopyrrole, quinophthalone, and truarycarbonium.
• perylene derivative is intended to include any substituted perylene that is visually detectable. However, the term is not intended to include perylene itself.
• anthracene derivative e.g., perylene, pyrene, anthracene or naphthalene derivative
• a derivative is an imide, bisimide or hydrazamimide derivative of perylene, anthracene, naphthalene, or pyrene.
• the visually detectable molecules of various embodiments of the invention are useful for a wide variety of analytical applications, such as biochemical and biomedical applications, in which there is a need to determine the presence, location, or quantity of a particular analyte (e.g., biomolecule).
• the invention provides a method for visually detecting a biomolecule, comprising: (a) providing a biological system with a visually detectable biomolecule comprising the compound of structure (I) linked to a biomolecule; and (b) detecting the biomolecule by its visible properties.
• the phrase "detecting the biomolecule by its visible properties” means that the biomolecule, without illumination or chemical or enzymatic activation, is observed with the naked eye, or with the aid of a optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners.
• a densitometer may be used to quantify the amount of visually detectable biomolecule present.
• the relative quantity of the biomolecule in two samples can be determined by measuring relative optical density. If the stoichiometry of dye molecules per biomolecule is known, and the extinction coefficient of the dye molecule is known, then the absolute concentration of the biomolecule can also be determined from a measurement of optical density.
• biological system is used to refer to any solution or mixture comprising one or more biomolecules in addition to the visually detectable biomolecule.
• biological systems include cells, cell extracts, tissue samples, electrophoretic gels, assay mixtures, and hybridization reaction mixtures.
• Solid support refers to any solid substrate known in the art for solid- phase support of molecules
• a microparticle refers to any of a number of small particles useful for attachment to compounds of the invention, including, but not limited to, glass beads, magnetic beads, polymeric beads, nonpolymeric beads, and the like.
• a microparticle comprises polystyrene beads.
• a “solid support reside” refers to the functional group remaining attached to a molecule when the molecule is cleaved from the solid support. Solid support residues are known in the art and can be easily derived based on the structure of the solid support and the group linking the molecule thereto.
• a “targeting moiety” is a moiety that selectively binds or associates with a particular target, such as an analyte molecule. "Selectively" binding or associating means a targeting moiety preferentially associates or binds with the desired target relative to other targets.
• the compounds disclosed herein include linkages to targeting moieties for the purpose of selectively binding or associating the compound with an analyte of interest (i.e., the target of the targeting moiety), thus allowing detection of the analyte.
• Exemplary targeting moieties include, but are not limited to, antibodies, antigens, nucleic acid sequences, enzymes, proteins, cell surface receptor antagonists, and the like.
• the targeting moiety is a moiety, such as an antibody, that selectively binds or associates with a target feature on or in a cell, for example a target feature on a cell membrane or other cellular structure, thus allowing for detection of cells of interest.
• a target feature on or in a cell for example a target feature on a cell membrane or other cellular structure, thus allowing for detection of cells of interest.
• Small molecules that selectively bind or associate with a desired analyte are also contemplated as targeting moieties in certain embodiments.
• Base pairing moiety refers to a heterocyclic moiety capable of hybridizing with a complementary heterocyclic moiety via hydrogen bonds (e.g., Watson-Crick base pairing).
• Base pairing moieties include natural and unnatural bases.
• Non-limiting examples of base pairing moieties are RNA and DNA bases such adenosine, guanosine, thymidine, cytosine and uridine and analogues thereof.
• Embodiments of the invention disclosed herein are also meant to encompass all compounds of structure (I) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
• isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
• Isotopically-labeled compounds of structure (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described below and in the following Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
• “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
• “Optional” or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
• “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution.
• Salt includes both acid and base addition salts.
• Acid addition salt refers to those salts which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic
• naphthalene-l,5-disulfonic acid naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, ⁇ -toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
• Base addition salt refers to those salts which are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
• dicyclohexylamine lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine,
• N-ethylpiperidine polyamine resins and the like.
• Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
• Crystallizations may produce a solvate of the compounds described herein.
• Embodiments of the present invention include all solvates of the described compounds.
• the term "solvate" refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
• the solvent may be water, in which case the solvate may be a hydrate.
• the solvent may be an organic solvent.
• the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
• the compounds of the invention may be true solvates, while in other cases the compounds of the invention may merely retain adventitious water or another solvent or be a mixture of water plus some adventitious solvent.
• Embodiments of the compounds of the invention may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
• Embodiments of the present invention are meant to include all such possible isomers, as well as their racemic and optically pure forms.
• Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
• Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
• HPLC high pressure liquid chromatography
• stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
• the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
• a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
• the present invention includes tautomers of any said compounds.
• Various tautomeric forms of the compounds are easily derivable by those of ordinary skill in the art.
• embodiments of the present invention are directed to dimers and higher polymers of fluorescent and/or colored moieties.
• the fluorescent and or colored moieties are linked by a phosphorous-containing linkage.
• the linker helps to maintain sufficient spatial distance between the fluorescent and/or colored moieties such that intramolecular quenching is reduced or eliminated, thus resulting in a dye compound having a high molar "brightness" (e.g., high fluorescence emission).
• the linker increases the water solubility of the fluorescent and/or colored moiety, which are typically hydrophobic and poorly water soluble.
• M is, at each occurrence, independently a monovalent moiety
• M' is, at each occurrence, independently a divalent moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation;
• L, L 2 and L 3 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker;
• L 1 is at each occurrence, independently either: i) an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker; or ii) a linker comprising a functional group capable of formation by reaction of two complementary reactive groups;
• L 4 is, at each occurrence, independently an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, carbocyclic or heterocyclic linker;
• R 1 is, at each occurrence, independently H, alkyl or alkoxy
• R 4 is, at each occurrence, independently OH, SH, O “ , S " , OR d or SRa,
• R 5 is, at each occurrence, independently oxo, thioxo or absent;
• R a is O or S;
• R b is OH, SH, O " , S " , OR d or SR d ;
• R c is OH, SH, O " , S " , OR d , OL', SR d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkylether, alkoxyalkylether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether;
• R d is a counter ion
• Q is, at each occurrence, independently a moiety comprising a reactive group, or protected analogue thereof, capable of forming a covalent bond with an analyte molecule, a targeting moiety, a solid support or a complementary reactive group Q';
• L' is, at each occurrence, independently a linker comprising a covalent bond to Q, a linker comprising a covalent bond to a targeting moiety, a linker comprising a covalent bond to an analyte molecule, a linker comprising a covalent bond to a solid support, a linker comprising a covalent bond to a solid support residue, a linker comprising a covalent bond to a nucleoside or a linker comprising a covalent bond to a further compound of structure (I);
• n 1 and m 2 are, at each occurrence, independently an integer of zero or greater;
• n, x and y are each independently an integer of zero or greater for each integral value of z;
• z is an integer of 1 or greater
• x is 1 or greater for at least one integral value of z, and at least one of n or y is 1 or greater for at least one integral value of z.
• M is, at each occurrence, independently a monovalent moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation;
• M' is, at each occurrence, independently a divalent moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation;
• L, L 2 and L 3 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker;
• L 1 is at each occurrence, independently either: i) an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker; or ii) a linker comprising a functional group capable of formation by reaction of two complementary reactive groups;
• L 4 is, at each occurrence, independently an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, carbocyclic or heterocyclic linker;
• R 1 is, at each occurrence, independently H, alkyl or alkoxy
• R d is a counter ion
• R 4 is, at each occurrence, independently OH, SH, O “ , S " , OR d or SR d ;
• R 5 is, at each occurrence, independently oxo, thioxo or absent;
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule, a solid support or a complementary reactive group Q';
• n 1 and m 2 are, at each occurrence, independently an integer of zero or greater;
• n, x and y are each independently an integer of zero or greater for each integral value of z;
• z is an integer of 1 or greater
• x is 1 or greater for at least one integral value of z
• at least one of n or y is 1 or greater for at least one integral value of z.
• y is 1 or greater for at least one integral value of z.
• n is 1 or greater for at least one integral value of z.
• the compound has the following structure (IA):
• y is an integer of 1 or greater, for example an integer from 1 to 10.
• the linker L is selected to provide the desired spacing between M' groups, and in certain embodiments to provide increased water solubility to the compounds.
• L 1 is at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker.
• L 1 is at each occurrence, independently a linker comprising a functional group capable of formation by reaction of two complementary reactive groups, for example a Q group.
• L is, at each occurrence, independently an alkylene linker, for example a Ci-C 6 alkylene linker.
• L is a C 3 linker, such as a propylene linker.
• M' is chosen based on the desired end use application.
• M' is a bivalent moiety, meaning that it is attached to the rest of the compound of structure (I) at two positions.
• M' is, at each occurrence, independently a bivalent: dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his- fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl- difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,
• M' is, at each occurrence, independently a bivalent: p-terphenyl, perylene, azobenzene, phenazine, phenanthroline, acridine, thioxanthrene, chrysene, rubrene, coronene, cyanine, perylene imide, or perylene amide or derivative thereof.
• M' is, at each occurrence, independently a bivalent: coumarin dye, resorufin dye, dipyrrometheneboron difluoride dye, ruthenium bipyridyl dye, energy transfer dye, thiazole orange dye, polymethine or N-aryl-1,8- naphthalimide dye.
• M' is, at each occurrence, independently a bivalent: pyrene, perylene, perylene monoimide or 6-FAM or derivative thereof.
• M' at each occurrence, independently has one of the following structures:
• brackets i.e., [ ]
• brackets i.e., [ ]
• two hydrogen atoms have been replaced with a bond to L or the appropriate group when L is absent.
• M' at each occurrence, has the following structure:
• the various linkers and substituents e.g., R 1 , R 2 , R 3 , R 4 , R 5 , L, L', L 1 , L 2 , L 3 , L 4 , Q, M and M'
• the optional substituent is selected to optimize the water solubility or other property of the compound of structure (I).
• each alkyl, alkoxy, alkylether , alkoxyalkylether, phosphoalkyl, thiophosphoalkyl, phosphoalkylether and thiophosphoalkylether in the compound of structure (I) is optionally substituted with one more substituent selected from the group consisting of hydroxyl, alkoxy, alkylether , alkoxyalkylether, sulfhydryl, amino, alkylamino, carboxyl, phosphate, thiophosphate, phosphoalkyl,
• the linker L 1 can be used as a point of attachment of the M moiety to the remainder of the compound.
• a synthetic precursor to the compound of structure (I) is prepared, and the M moiety is attached to the synthetic precursor using any number of facile methods known in the art, for example methods referred to as "click chemistry.”
• click chemistry any reaction which is rapid and substantially irreversible can be used to attach M to the synthetic precursor to form a compound of structure (I).
• Exemplary reactions include the copper catalyzed reaction of an azide and alkyne to form a triazole (Huisgen 1, 3-dipolar cycloaddition), reaction of a diene and dienophile (Diels- Alder), strain-promoted alkyne-nitrone cycloaddition, reaction of a strained alkene with an azide, tetrazine or tetrazole, alkene and azide [3+2] cycloaddition, alkene and tetrazine inverse-demand Diels-Alder, alkene and tetrazole photoreaction and various displacement reactions, such as displacement of a leaving group by nucleophilic attack on an electrophilic atom.
• a triazole Huisgen 1, 3-dipolar cycloaddition
• Diels- Alder Diels- Alder
• strain-promoted alkyne-nitrone cycloaddition reaction of a
• Exemplary displacement reactions include reaction of an amine with: an activated ester; an N- hydroxysuccinimide ester; an isocyanate; an isothioscyanate or the like.
• the reaction to form L 1 may be performed in an aqueous environment.
• L 1 is a functional group which is the product of one of the foregoing "click" reactions.
• the functional group can be formed by reaction of an aldehyde, oxime, hydrazone, alkyne, amine, azide, acylazide, acylhalide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester (e.g., N-hydroxysuccinimide ester), ketone, ⁇ , ⁇ -unsaturated carbonyl, alkene, maleimide, a- haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin or thiirane functional group with a complementary reactive group.
• the functional group can be formed by reaction of an alkyne and an azide. In other embodiments, for at least one occurrence of L 1 , the functional group can be formed by reaction of an amine (e.g., primary amine) and an N-hydroxysuccinimide ester or isothiocyanate.
• an amine e.g., primary amine
• the functional group comprises an alkene, ester, amide, thioester, disulfide, carbocyclic, heterocyclic or heteroaryl group. In more embodiments, for at least one occurrence of L 1 , the functional group comprises an alkene, ester, amide, thioester, thiourea, disulfide, carbocyclic, heterocyclic or heteroaryl group. In other embodiments, the functional group comprises an amide or thiourea. In some more specific embodiments, for at least one occurrence of L 1 , L 1 is a linker comprising a triazolyl functional group. While in other embodiments, for at least one occurrence of L 1 , L 1 is a linker comprising an amide or thiourea functional group.
• ⁇ ⁇ has the following structure:
• L a and L are each independently optional linkers.
• L ⁇ M has the following structure:
• L a and L are each independently optional linkers.
• L la or L lb is absent. In other embodiments, L la or L lb , or both, is present.
• L la and L lb when present, are each independently alkylene or heteroalkylene.
• L la and L lb when present, independently have one of the following structures:
• L 2 , L 3 and L 4 are, at each occurrence, independently Ci-C 6 alkylene, C 2 -C6 alkenylene or C 2 -C6 alkynylene.
• L 4 is, at each occurrence, independently Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene.
• L 4 is an ethylene oxide linker, for example a triethylene oxide or hexaethylene oxide linker.
• L 4 is a carbocyclic or heterocyclic linker, for example a multi cyclic, fused carbocyclic or heterocyclic linker.
• R 4 is, at each occurrence, independently OH, O " or OR d . It is understood that "OR d “ and “SR d “ are intended to refer to O " and S " associated with a cation.
• the disodium salt of a phosphate group may be represented as:
• R d is sodium (Na + ).
• R 5 is, at each occurrence, oxo. In some different embodiments of any of the foregoing compounds, R 1 is
• R e is OL'.
• Q a targeting moiety
• an analyte e.g., analyte molecule
• solid support e.g., alyte molecule
• solid support residue e.g., a nucleoside or a further compound of structure (I).
• the linker L' can be any linker suitable for attaching Q, a targeting moiety, an analyte (e.g., analyte molecule), a solid support, a solid support residue, a nucleoside or a further compound of structure (I) to the compound of structure (I).
• analyte e.g., analyte molecule
• L' is a compound selected to increase or optimize water solubility of the compound.
• L' is a compound selected to increase or optimize water solubility of the compound.
• L' comprises an alkylene oxide or phosphodiester moiety, or combinations thereof.
• L' has the following structure:
• n are independently an integer from 1 to 10;
• R e is H, an electron pair or a counter ion
• L" is R e or a direct bond or linkage to: Q, a targeting moiety, an analyte (e.g., analyte molecule), a solid support, a solid support residue, a nucleoside or a further compound of structure (I).
• m" is an integer from 4 to 10, for example 4, 6 or 10.
• n" is an integer from 3 to 6, for example 3, 4, 5 or 6.
• L" is an alkylene or heteroalkylene moiety. In some other certain embodiments, L" comprises an alkylene oxide, phosphodiester moiety, sulfhydryl, disulfide or maleimide moiety or combinations thereof.
• the targeting moiety is an antibody or cell surface receptor antagonist.
• L' is a linkage to a solid support, a solid support residue or a nucleoside.
• Solid supports comprising an activated deoxythymidine (dT) group are readily available, and in some embodiments can be employed as starting material for preparation of compounds of structure (I). Accordingly, in s :
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule or a solid support. In other embodiments, Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with a complementary reactive group Q'.
• Q' is present on a further compound of structure (I) (e.g., in the R 2 or R 3 position), and Q and Q' comprise complementary reactive groups such that reaction of the compound of structure (I) and the further compound of structure (I) results in covalently bound dimer of the compound of structure (I).
• Multimer compounds of structure (I) can also be prepared in an analogous manner and are included within the scope of embodiments of the invention.
• the type of Q group and connectivity of the Q group to the remainder of the compound of structure (I) is not limited, provided that Q comprises a moiety having appropriate reactivity for forming the desired bond.
• the Q is a moiety which is not susceptible to hydrolysis under aqueous conditions, but is sufficiently reactive to form a bond with a corresponding group on an analyte molecule or solid support (e.g., an amine, azide or alkyne).
• analyte molecule or solid support e.g., an amine, azide or alkyne
• Certain embodiments of compounds of structure (I) comprises Q groups commonly employed in the field of bioconjugati on. For example in some
• Q comprises a nucleophilic reactive group, an electrophilic reactive group or a cycloaddition reactive group.
• Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, a-haloamide, biotin, amino or maleimide functional group.
• the activated ester is an N- succinimide ester, imidoester or polyflourophenyl ester.
• the alkyne is an alkyl azide or acyl azide.
• Q groups can be conveniently provided in protected form to increase storage stability or other desired properties, and then the protecting group removed at the appropriate time for conjugation with, for example, a targeting moiety or analyte.
• Q groups include "protected forms" of a reactive group, including any of the reactive groups described above and in the Table 1 below.
• a "protected form” of Q refers to a moiety having lower reactivity under predetermined reaction conditions relative to Q, but which can be converted to Q under conditions, which preferably do not degrade or react with other portions of the compound of structure (I).
• One of skill in the art can derive appropriate protected forms of Q based on the particular Q and desired end use and storage conditions. For example, when Q is SH, a protected form of Q includes a disulfide, which can be reduce to reveal the SH moiety using commonly known techniques and reagents.
• the Q moiety is conveniently masked (e.g., protected) as a disulfide moiety, which can later be reduced to provide an activated Q moiety for binding to a desired analyte molecule or targeting moiety.
• the Q moiety may be masked as a disulfide havin the following structure:
• R is an optionally substituted alkyl group.
• Q is provided as a disulfide moiety havin the following structure:
• n is an integer from 1 to 10, for example 6.
• the SH moiety will tend to form disulfide bonds with another sulfhydryl group on another compound of structure (I). Accordingly, some embodiments include compounds of structure (I), which are in the form of disulfide dimers, the disulfide bond being derived from SH Q groups.
• the analyte molecule is a nucleic acid, amino acid or a polymer thereof.
• the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• the solid support is a polymeric bead or nonpolymeric bead.
• m is, at each occurrence, independently an integer from 1 to 10, 3 to 10 or 7 to 9. In other embodiments, m is, at each occurrence, independently an integer from 1 to 5, for example 1, 2, 3, 4 or 5. In other embodiments, m is, at each occurrence, independently an integer from 5 to 10, for example 5, 6, 7, 8, 9 or 10. In other embodiments, each occurrence of m is an integer of one or greater. For example, in some embodiments each occurrence of m is an integer of two or greater or three or greater.
• m 2 is 1 at each occurrence.
• the fluorescence intensity can also be tuned by selection of different values of n.
• n is an integer from 1 to 100. In other words,
• n is an integer from 1 to 10. In some embodiments, n is 1.
• M is selected based on the desired optical properties, for example based on a desired color and/or fluorescence emission wavelength.
• M is the same at each occurrence; however, it is important to note that each occurrence of M need not be an identical M, and certain embodiments include compounds wherein M is not the same at each occurrence.
• each M is not the same and the different M moieties are selected to have absorbance and/or emissions for use in fluorescence resonance energy transfer (FRET) methods.
• FRET fluorescence resonance energy transfer
• the different M moieties are selected such that absorbance of radiation at one wavelength causes emission of radiation at a different wavelength by a FRET mechanism.
• Exemplary M moieties can be appropriately selected by one of ordinary skill in the art based on the desired end use.
• Exemplary M moieties for FRET methods include fluorescein and 5-TAMRA (5-carboxytetramethylrhodamine, succinimidyl ester) dyes.
• M may be attached to the remainder of the molecule from any position (i.e., atom) on M.
• position i.e., atom
• M may be attached to the remainder of molecule from any position (i.e., atom) on M.
• One of skill in the art will recognize means for attaching M to the remainder of molecule. Exemplary methods include the "click" reactions described herein.
• M is a fluorescent or colored moiety. Any fluorescent and/or colored moiety may be used, for examples those known in the art and typically employed in colorimetric, UV, and/or fluorescent assays may be used.
• M moieties which are useful in various embodiments of the invention include, but are not limited to: Xanthene derivatives (e.g., fluorescein, rhodamine, Oregon green, eosin or Texas red); Cyanine derivatives (e.g., cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine or merocyanine); Squaraine derivatives and ring-substituted squaraines, including Seta, SeTau, and Square dyes; Naphthalene derivatives (e.g., dansyl and prodan derivatives); Coumarin derivatives; oxadiazole derivatives (e.g., pyridyloxazole, nitrobenzoxadiazole or benzoxadiazole); Anthracene derivatives (e.g., anthraquinones, including DRAQ5, DRAQ7 and
• CyTRAK Orange Pyrene derivatives such as cascade blue; Oxazine derivatives (e.g., Nile red, Nile blue, cresyl violet, oxazine 170); Acridine derivatives (e.g., proflavin, acridine orange, acridine yellow); Arylmethine derivatives: auramine, crystal violet, malachite green; and Tetrapyrrole derivatives (e.g., porphin, phthalocyanine or bilirubin).
• Oxazine derivatives e.g., Nile red, Nile blue, cresyl violet, oxazine 170
• Acridine derivatives e.g., proflavin, acridine orange, acridine yellow
• Arylmethine derivatives auramine, crystal violet, malachite green
• Tetrapyrrole derivatives e.g., porphin, phthalocyanine or bilirubin
• M moieties include: Cyanine dyes, xanthate dyes (e.g., Hex, Vic, Nedd, Joe or Tet); Yakima yellow; Redmond red; tamra; texas red and alexa fluor® dyes.
• M comprises three or more aryl or heteroaryl rings, or combinations thereof, for example four or more aryl or heteroaryl rings, or combinations thereof, or even five or more aryl or heteroaryl rings, or combinations thereof.
• M comprises six aryl or heteroaryl rings, or combinations thereof.
• the rings are fused.
• M comprises three or more fused rings, four or more fused rings, five or more fused rings, or even six or more fused rings.
• M is cyclic.
• M is cyclic.
• M is carbocyclic. In other embodiment, M is heterocyclic. In still other embodiments of the foregoing, M, at each occurrence, independently comprises an aryl moiety. In some of these embodiments, the aryl moiety is multicyclic. In other more specific examples, the aryl moiety is a fused-multicyclic aryl moiety, for example which may comprise at least 3, at least 4, or even more than 4 aryl rings.
• M at each occurrence, independently comprises at least one heteroatom.
• the heteroatom is nitrogen, oxygen or sulfur.
• M at each occurrence, independently comprises at least one substituent.
• the substituent is a fluoro, chloro, bromo, iodo, amino, alkylamino, arylamino, hydroxy, sulfhydryl, alkoxy, aryloxy, phenyl, aryl, methyl, ethyl, propyl, butyl, isopropyl, t-butyl, carboxy, sulfonate, amide, or formyl group.
• M at each occurrence, independently is a dimethylaminostilbene, quinacridone, fluorophenyl- dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9, 10- ethynyl anthracene or ter-naphthyl moiety.
• M is, at each occurrence
• M is, at each occurrence, independently a coumarin dye, resorufin dye, dipyrrometheneboron difluoride dye, ruthenium bipyridyl dye, energy transfer dye, thiazole orange dye, polymethine or N-aryl-l,8-naphthalimide dye.
• M at each occurrence is the same. In other embodiments, each M is different. In still more embodiments, one or more M is the same and one or more M is different.
• M is pyrene, perylene, perylene monoimide or 6-
• M has one of the following structures:
• M moieties comprising carboxylic acid groups are depicted in the anionic form (C0 2 " ) above, one of skill in the art will understand that this will vary depending on pH, and the protonated form (C0 2 H) is included in various embodiments.
• the compound of structure (I) has the following structure:
• y is an integer greater than 1, for example an integer from 1 to 10.
• the presently disclosed dye compounds are "tunable," meaning that by proper selection of the variables in any of the foregoing compounds, one of skill in the art can arrive at a compound having a desired and/or predetermined molar fluorescence (molar brightness).
• the tunability of the compounds allows the user to easily arrive at compounds having the desired fluorescence and/or color for use in a particular assay or for identifying a specific analyte of interest.
• all variables may have an effect on the molar fluorescence of the compounds, proper selection of M, M', m 1 , m 2 , n, x, y and z is believed to play an important role in the molar fluorescence of the compounds.
• a method for obtaining a compound having a desired molar fluorescence comprising selecting an M and/or M' moiety having a known fluorescence, preparing a compound of structure (I) comprising the M and/or M' moiety, and selecting the appropriate variables for m 1 , m 2 , n, x, y and z to arrive at the desired molar fluorescence.
• Molar fluorescence in certain embodiments can be expressed in terms of the fold increase or decrease relative to the fluorescence emission of the parent fluorophore (e.g., monomer).
• the molar fluorescence of the present compounds is l . lx, 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x lOx or even higher relative to the parent fluorophore.
• Various embodiments include preparing compounds having the desired fold increase in fluorescence relative to the parent fluorophore by proper selection of m and n.
• any of the foregoing compounds of structure (I) are included in a composition further comprising one or more cyclodextrin.
• the cyclodextrin helps to prevent or reduce intramolecular quenching of the dye moieties (e.g., fluorescent and/or colored moieties), thus resulting in a dye compound having a high molar "brightness" (e.g., high fluorescence emission).
• any cyclodextrin may be employed in practice of various embodiments, provided the cyclodextrins reduces or prevents intramolecular quenching of the dye moieties.
• a cyclodextrin having affinity for the particular compound of structure (I) are selected.
• the cyclodextrin is a-cyclodextrin, ⁇ - cyclodextrin or ⁇ -cyclodextrin.
• the cyclodextrin is ⁇ -cyclodextrin.
• such compositions comprise water.
• compositions comprising any of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other analyte molecules (e.g., biomolecules) are provided in various other portions of the fore molecules and one or more analyte molecules (e.g., biomolecules) are provided in various other organote molecules (e.g., biomolecules) are provided in various other organote molecules (e.g., biomolecules)
• compositions in analytical methods for detection of the one or more analyte molecules are also provided.
• the compounds are useful in various analytical methods.
• R 2 is a linker comprising a covalent linkage to an analyte molecule, such as a biomolecule.
• a linker comprising a covalent linkage to an analyte molecule, such as a biomolecule.
• a biomolecule such as a biomolecule.
• a nucleic acid, amino acid or a polymer thereof e.g., polynucleotide or polypeptide.
• the biomolecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• R 2 is a linker comprising a covalent linkage to a solid support such as a microparticle.
• a solid support such as a microparticle.
• the microparticle is a polymeric bead or nonpolymeric bead.
• said optical response is a fluorescent response.
• said sample comprises cells, and some embodiments further comprise observing said cells by flow cytometry.
• the method further comprises distinguishing the fluorescence response from that of a second fluorophore having detectably different optical properties.
• the disclosure provides a method for visually detecting an analyte molecule, such as a biomolecule, comprising:
• the analyte molecule is a nucleic acid, amino acid or a polymer thereof (e.g., polynucleotide or polypeptide). In still more embodiments, the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• a method for visually detecting an analyte molecule, such as a biomolecule comprising:
• a method for visually detecting an analyte molecule comprising:
• exemplary methods include a method for detecting an analyte, the method comprising:
• the analyte is a particle, such as a cell
• the method includes use of flow cytometry.
• the compound may be provided with a targeting moiety, such as an antibody, for selectively associating with the desired cell, thus rendering the cell detectable by any number of techniques, such as visible or fluorescence detection.
• a targeting moiety such as an antibody
• Appropriate antibodies can be selected by one of ordinary skill in the art depending on the desired end use.
• Exemplary antibodies for use in certain embodiments include UCHT1 and MOPC-21.
• Embodiments of the present compounds thus find utility in any number of methods, including, but not limited: cell counting; cell sorting; biomarker detection; quantifying apoptosis; determining cell viability; identifying cell surface antigens; determining total DNA and/or RNA content; identifying specific nucleic acid sequences (e.g., as a nucleic acid probe); and diagnosing diseases, such as blood cancers.
• the compounds of structure (I) can be used in various for analysis of cells. For example, by use of flow cytometry, the compounds can be used to discriminate between live and dead cells, evaluate the health of cells (e.g., necrosis vs. early apoptitic vs. late apoptitic vs. live cell), tracking ploidy and mitosis during the cell cycle and determining various states of cell proliferation. While not wishing to be bound by theory, it is believed that embodiments of the compounds of structure (I) preferentially bind or otherwise associate with positively charged moieties. Accordingly, in some embodiments the compounds may be used in methods for determining the presence of non-intact cells, for example necrotic cells.
• the presence of necrotic cells can be determined by admixing a sample containing cells with a compound of structure (I) and analyzing the mixture by flow cytometry.
• the compound of structure (I) binds or associates with necrotic cells, and thus their presence is detectable under flow cytometry conditions.
• embodiments of the staining methods of employing compounds of structure (I) do not require a protein-free incubation buffer, and thus the methods are more efficient to perform than related known methods.
• the invention provides a method for determining the presence of dead cells in a sample, the method comprising contacting the sample with a compound of structure (I), thereby binding or associating the compound with the dead cells, and observing a fluorescent signal from the compound bound or associated with the dead cells.
• some embodiments comprise use of flow cytometry to observe the compound bound or associated with the dead cells.
• certain methods do not require use of reactive groups to bind or associate with the dead cells.
• the compounds can be used in related methods for determine the presence of positively charged moieties in intact or non- intact cells, apoptitic bodies, depolarized membranes and/or permealized membranes.
• embodiments of the compounds of structure (I) find utility in various disciplines and methods, including but not limited to: imaging in endoscopy procedures for identification of cancerous and other tissues; single-cell and/or single molecule analytical methods, for example detection of polynucleotides with little or no amplification; cancer imaging, for example by including a targeting moiety, such as an antibody or sugar or other moiety that preferentially binds cancer cells, in a compound of structure (I) to; imaging in surgical procedures; binding of histones for identification of various diseases; drug delivery, for example by replacing the M moiety in a compound of structure (I) with an active drug moiety; and/or contrast agents in dental work and other procedures, for example by preferential binding of the compound of structure (I) to various flora and/or organisms.
• a targeting moiety such as an antibody or sugar or other moiety that preferentially binds cancer cells
• any embodiment of the compounds of structure (I), as set forth above, and any specific choice set forth herein for a R 1 , R 2 , R 3 , R 4 , R 5 , L, L', L 1 , L 2 , L 3 , L 4 , M, M', m 1 , m 2 , n, x, y and/or z variable in the compounds of structure (I), as set forth above, may be independently combined with other embodiments and/or variables of the compounds of structure (I) to form embodiments of the inventions not specifically set forth above.
• Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
• Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like.
• Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like.
• Suitable protecting groups for mercapto include -C(0)-R" (where R" is alkyl, aryl or arylalkyl), /?-methoxybenzyl, trityl and the like.
• Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
• Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.
• the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
• Embodiments of the compounds of structure (I) are prepared according to the general procedures set forth in the Examples. Methods useful for preparation of intermediates for preparation of compounds of structure (I) are set forth below.
• Reaction Scheme I illustrates an exemplary method for preparation of intermediates useful for preparation of compounds of structure (I).
• reaction Scheme I where R , L , L , L , G and M are as defined above, and R and R are as defined above or are protected variants thereof, a compound of structure a, which can be purchased or prepared by well-known techniques, is reacted with M-G' to yield compounds of structure b.
• G and G' represent functional groups having complementary reactivity (i.e., functional groups which react to form a covalent bond).
• G' may be pendant to M or a part of the structural backbone of M.
• G and G may be any number of functional groups described herein, such as alkyne and azide, respectively, amine and activated ester, respectively or amine and isothiocyanate, respectively, and the like.
• Multimer compounds are prepared by reacting the desired number of compounds of structure b sequentially with the appropriate phosphoramidite reagent under DNA synthesis conditions.
• the compounds are prepared by first synthesizing a dimeric or oligomeric compound having the following structure d under typical DNA synthesis conditions:
• DNA synthesis methods are well-known in the art. Briefly, two alcohol groups, for example R 2 and R 3 in intermediates b or d above, are functionalized with a dimethoxytrityl (DMT) group and a 2-cyanoethyl-N,N-diisopropylamino
• DMT dimethoxytrityl
• the phosphoramidite group is coupled to an alcohol group, typically in the presence of an activator such as tetrazole, followed by oxidation of the phosphorous atom with iodine.
• the dimethoxytrityl group can be removed with acid (e.g., chloroacetic acid) to expose the free alcohol, which can be reacted with a phosphoramidite group.
• the 2-cyanoethyl group can be removed after oligomerization by treatment with aqueous ammonia.
• Preparation of the phosphoramidites used in the oligomerization methods is also well-known in the art.
• a primary alcohol e.g., R 3
• a secondary alcohol e.g., R 2
• R 3 a primary alcohol
• R 2 a secondary alcohol
• R 2 is then functionalized as a phosphoramidite by reaction with an appropriate reagent such as 2-cyanoethyl ⁇ , ⁇ -dissopropylchlorophosphoramidite.
• Phosphoramidites and precursor molecules were analyzed using a Waters Acquity UHPLC system with a 2.1mm x 50mm Acquity BEH-C18 column held at 45°C, employing an acetonitrile/water mobile phase gradient.
• Molecular weights for monomer intermediates were obtained using tropylium cation infusion enhanced ionization on a Waters/Micromass Quattro micro MS/MS system (in MS only mode). 1 Excitation and emission profiles experiments were recorded on a Cary Eclipse spectra photometer.
• Dibromoperylene (330mg, 0.8mmol) was added and the mixture degassed for 15min by directly bubbling nitrogen through the mixture via a long needle. The needle was removed and the [ ⁇ , - Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (59mg, 0.08 mmol) was added in a single portion.
• the reaction vessel was reequipped with the reflux condenser, placed under nitrogen and refluxed overnight. The mixture was cooled to room temperature, diluted with dichloromethane (100 mL), filtered through celite and concentrated. The oily residue was purified by silica gel chromatography using a hexanes/ethyl acetate gradient to afford the desired diol as an oil (129mg, 30%).
• Dibromoperylene 2000mg, 4.9mmol was added and the mixture degassed for 15min by directly bubbling nitrogen through the mixture via a long needle. The needle was removed and the [1, - Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (357mg, 0.5mmol) was added in a single portion.
• the reaction vessel was reequipped with the reflux condenser, placed under nitrogen and refluxed overnight. The mixture was cooled to room temperature, diluted with dichloromethane (250 mL), filtered through celite and concentrated.
• a phosphoramidite useful for preparation of certain embodiments of compounds of structure (I) was prepared as follows.
• carbamate 7 ( ⁇ 3.1g). Pyridine was added to the flask (270mL) and stirring was initiated. Once the carbamate had been dissolved, the solution was placed on ice and stirred for 15min under nitrogen. Dimethoxytrityl chloride (5.9g) was added to the flask by powder funnel in a single portion. The flask was repurged with nitrogen and stirred at OC for lh. The flask was removed from ice and stirred at room temperature overnight. Methanol was added (lOmL) and the mixture stirred for lOmin. The mixture was concentrated on the rotovap and purified by silica gel chromatography. Product fraction were determined by TLC, pooled and concentrated to a final oil to afford mono-protected diol 8 (3.3g).
• FAM-NHS ester 2 (2.24g).
• Dichloromethane 35mL was added to the flask, stirring was initiated, flask placed under nitrogen and cooled on ice.
• 2-(2-aminoethoxy)ethanol 420 ⁇ was dissolved in dichloromethane (35mL), methanol (7mL) and triethylamine (1.5mL) and the resulting solution was charged to the addition funnel.
• the amine solution was added dropwise to the NHS ester over 30 minutes.
• the final solution was stirred for lh at 0C, the flask was removed from the ice bath and stirred at room temperature for 2h.
• the reaction mixture was concentrated and the crude product was purified by silica gel chromatography. Product fractions were examined by TLC and LC/MS and pooled to afford 1.6g (72%).
• FAM-tosylate 4 (1.8g) and DMF (15mL) was added and the mixture was stirred to effect dissolution.
• sodium azide 830mg
• the mixture was poured onto lOOmM citric acid (150mL) and ethyl acetate (150mL) in an extraction funnel. The layers were partitioned and the organic layer retained. The aqueous layer was extracted with ethyl acetate two additional times. The organic layers were combined and dried over sodium sulfate. The solution was filtered and concentrated by rotary evaporation.
• 3-, 5- and 10-mer polyalkyne oligomers were prepared from the phosphoramidite of Example 4.
• a representative 3-mer dye was prepared as follows:
• 3-, 5- and 10-mer dyes with either a coumarin or fluorescein moiety were prepared in an analogous manner.
• the oligomer dyes thus prepared are conjugated to compounds prepared according to Example 3.
• the phosphoramidites of Examples 1 and 4 are used in combination with appropriate spacer phosphoramidites (commercially available from Glenn Research) under standard DNA coupling procedures as described above to yield an oligomer which can be converted to a compound of structure (I) as described above.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Ecology (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Materials Engineering (AREA)
• Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
• Plural Heterocyclic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Compositions Of Macromolecular Compounds (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=59034852

Family Applications (1)

Country Status (10)

Cited By (16)

Families Citing this family (14)

Citations (4)

Family Cites Families (156)

• 2017
  • 2017-05-11 EP EP17729231.5A patent/EP3455300A1/en not_active Ceased
  • 2017-05-11 AU AU2017264861A patent/AU2017264861B2/en active Active
  • 2017-05-11 US US16/300,422 patent/US11685835B2/en active Active
  • 2017-05-11 WO PCT/US2017/032206 patent/WO2017197144A1/en not_active Ceased
  • 2017-05-11 BR BR112018073199-4A patent/BR112018073199A2/pt not_active Application Discontinuation
  • 2017-05-11 CN CN201780028255.0A patent/CN109071961B/zh active Active
  • 2017-05-11 JP JP2018558754A patent/JP7071286B2/ja active Active
  • 2017-05-11 KR KR1020187035995A patent/KR102526802B1/ko active Active
  • 2017-05-11 RU RU2018143594A patent/RU2018143594A/ru not_active Application Discontinuation
  • 2017-05-11 CA CA3021419A patent/CA3021419A1/en active Pending

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events